|

[212Pb]VMT-alpha-NET Clinical Trials

2 actively recruiting trials across 1 location

Pipeline

Phase 1: 1Phase 1/2: 1

Top Sponsors

  • National Cancer Institute (NCI)2

Indications

  • Gastrointestinal Neuroendocrine Tumors2
  • Somatostatin Receptor Positive2
  • Cancer2
  • Pheochromocytoma/Paragangliomas1
  • Small Cell Lung Cancers1

Bethesda, Maryland2 trials

Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

National Institutes of Health Clinical Center

Phase 1/2
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

National Institutes of Health Clinical Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.